

Special Issue

Mesenchymal Stromal (Stem) Cells

Message from the Guest Editor

Since the first description of mesenchymal stromal(/stem) cells (MSCs) by Friedenstein and colleagues in 1967, these cells have been used in more than 2000 registered clinical trials ([Clinicaltrials.gov](https://clinicaltrials.gov)). MSCs have been used in a wide range of diseases, including musculoskeletal defects, disorders of the immune system (e.g., autoimmune diseases), and myocardial infarction. This Special Issue, on the subject of stromal cells intends to cover several aspects of stromal cells, from bench to bedside! Thus, several relevant subjects such as tissue sources, biology, in vitro assays, preclinical/clinical studies, regulatory/ethical aspects, and commercialization will be discussed in this Issue. Based on MSCs' mechanisms of action, most clinical applications concentrate on inflammatory disorders and regenerative medicine. This has been extensively discussed, but gathering the latest findings in a collection still is required for scientists, physicians and investors for future planning. We invite colleagues and authors to submit original research and review articles that are aligned with the scope of this Special Issue.

Guest Editor

Dr. Behnam Sadeghi

Department of CLINTEC, Karolinska Institutet, TCR, KFC, NOVUM, Plan 6, Hälsovägen 7-9, 141 57 Huddinge, Sweden

Deadline for manuscript submissions

closed (30 September 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/134156

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).